Home / IL-4 / Recombinant Human IL-4 Protein, Animal-Free

Recombinant Human IL-4 Protein, Animal-Free

Catalog #: BT-004-AFL Datasheet / COA / SDS
GMP Version Available: BT-004-GMP
GMP
Intended for preclinical researchers who may transition to GMP IL-4 for their clinical work
Catalog # Availability Size / Price Qty
BT-004-AFL-01M
BT-004-AFL-050

Request an Animal-Free Protein Sample. For a limited time, we are offering customers the opportunity to try a sample of any Animal-Free RUO protein at no charge. Request a sample of Animal-Free IL-4.

Recombinant Human IL-4 Protein Bioactivity Comparison.
3 Images
Product Details
FAQs
Supplemental Products
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IL-4 Protein, Animal-Free Summary

Learn more about Animal-Free Recombinant Proteins

Product Specifications

Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED50 for this effect is 0.0400-0.320 ng/mL.
The specific activity of Animal-Free™ Recombinant Human IL-4 is >1.0x107 IU/mg, which is calibrated against the human IL-4 WHO International Standard (NIBSC code: 88/656).
Source
E. coli-derived human IL-4 protein
His25-Ser153, with an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.
Accession #
P05112.1
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
15.1 kDa
SDS-PAGE
13 kDa, under reducing conditions.

Product Datasheets

You must select a language.

x

BT-004-AFL

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

BT-004-AFL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS. 
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity View Larger

As an alternative, please consider our next generation Recombinant Human IL-4 Protein, (BT-004-GMP). This has equivalent bioactivity to Recombinant Human IL-4 Proteins (BT-004) and Catalog # BT-004-AFL.These combine R&D Systems quality with scalability that allows for a solid supply chain. All Recombinant Human IL-4 proteins are measured in a cell proliferation assay using TF-1 human erythroleukemic cell line.

Bioactivity View Larger

Recombinant Human IL‑4 stimulates cell proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.0400‑0.320 ng/mL.

SDS-PAGE View Larger

2 μg/lane of Animal-Free™ Recombinant Human IL‑4 Protein (Catalog # BT-004-AFL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 13 kDa underreducing conditions.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-4

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa‑18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1‑3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four alpha -helix structure (4). Human IL-4 is synthesized with a 24 aa signal sequence. Alternate splicing generates an isoform with a 16 aa internal deletion. Mature human IL-4 shares 55%, 39% and 43% aa sequence identity with bovine, mouse, and rat IL-4, respectively. Human, mouse, and rat IL-4 are species-specific in their activities (5‑7). IL-4 exerts its effects through two receptor complexes (8, 9). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha and the common gamma  chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and ‑21). The type II receptor on nonhematopoietic cells consists of IL-4 R alpha and IL‑13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgG4 and IgE in human B cells, acquisition of the Th2 phenotype by naïve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (10‑13). IL-4 plays a dominant role in the development of allergic inflammation and asthma (12, 14).

Due to its role in the differentiation of certain immune cell types, IL-4 is commonly used in combination with other growth factors to transform induced pluripotent stem cells into dendritic cells in high numbers. These dendritic cells can then be used for research or clinical applications to improve disease modeling, for screening and cell therapies (15). Study of IL-4 signaling has led to the development of monoclonal antibodies that can block the signaling pathway at various steps to mitigate the inflammatory response in certain autoimmune diseases (16, 17). While IL-4 has the capacity to improve immune functions, treatments involving IL-4 have not been utilized due to the dangerous side effects that may result from IL-4 signaling in non-immune cells (16). Blockade of IL-4 signaling also has been studied as a therapeutic target to suppress inflammation in the tumor microenvironment (18). Use of IL-4 suppressors can also improve the efficacy of anti-tumor immunotherapies, as blocking IL-4 enhances activity of tumor-specific T lymphocytes (19, 20).

References
  1. Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. 33:109.
  2. Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. 17:1.
  3. Yokota, T. et al. (1986) Proc. Natl. Acad. Sci. 83:5894.
  4. Redfield, C. et al. (1991) Biochemistry 30:11029.
  5. Ramirez, F. et al. (1988) J. Immunol. Meth. 221:141.
  6. Leitenberg, D. and T.L. Feldbush (1988) Cell. Immunol. 111:451.
  7. Mosman, T.R. et al. (1987) J. Immunol. 138:1813.
  8. Mueller, T.D. et al. (2002) Biochim. Biophys. Acta 1592:237.
  9. Nelms, K. et al. (1999) Annu. Rev. Immunol. 17:701.
  10. Paludan, S.R. (1998) Scand. J. Immunol. 48:459.
  11. Corthay, A. (2006) Scand. J. Immunol. 64:93.
  12. Ryan, J.J. et al. (2007) Crit. Rev. Immunol. 27:15.
  13. Grone, A. (2002) Vet. Immunol. Immunopathol. 88:1.
  14. Rosenberg, H.F. et al. (2007) J. Allergy Clin. Immunol. 119:1303.
  15. Flosdorf, N. & Zenke, M. (2022) Eur. J. Immunol. 52:1880.
  16. Junttila, I.S. (2018) Front Immunol. 9:888.
  17. Keegan, A.D. et al. (2021) Fac Rev. 10:71.
  18. Bankaitis, K.V. & Fingleton, B. (2016) Clin. Exp. Metastasis. 32:847.
  19. Mirlekar, B. (2022) SAGE Open Med. 10:1.
  20. Ilto, S. E. et al. (2017) Cancer Immunol Immunother. 66:1485.
Long Name
Interleukin 4
Entrez Gene IDs
3565 (Human); 16189 (Mouse); 287287 (Rat); 397225 (Porcine); 280824 (Bovine); 403785 (Canine); 574281 (Primate); 100302454 (Rabbit)
Alternate Names
B cell growth factor 1; BCDF; B-cell stimulatory factor 1; BCGF1; BCGF-1; binetrakin; BSF1; BSF-1; IL4; IL-4; IL-4B_cell stimulatory factor 1; IL4E12; interleukin 4; interleukin-4; Lymphocyte stimulatory factor 1; MGC79402; pitrakinra

Manufacturing Specifications

Animal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.  

 Production

  • All molecular biology procedures use animal-free media and dedicated labware.
  • Dedicated fermentors are utilized in committed animal-free areas.

Purification

  • Protein purification columns are animal-free.
  • Bulk proteins are filtered using animal-free filters.
  • Purified proteins are stored in animal-free containers in a dedicated cold storage room.

    Quality Assurance

    • Low Endotoxin Level.
    • No impairment of biological activity.
    • High quality product obtained under stringent conditions.
    • For ex vivo research or bioproduction, additional documentation can be provided.

    Please read our complete Animal-Free Statement

    FAQs

    No product specific FAQs exist for this product, however you may

    View all Proteins and Enzyme FAQs
    Loading...

    Reviews for Recombinant Human IL-4 Protein, Animal-Free

    There are currently no reviews for this product. Be the first to review Recombinant Human IL-4 Protein, Animal-Free and earn rewards!

    Have you used Recombinant Human IL-4 Protein, Animal-Free?

    Submit a review and receive an Amazon gift card.

    $25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

    $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

    Submit a Review